HAEK:F:F-Haemato AG (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 16.7

Change

+0.10 (+0.60)%

Market Cap

USD 0.11B

Volume

557.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

-0.20 (-0.67%)

USD 67.42B
MRK:F Merck & Company Inc

+2.05 (+1.37%)

USD 66.78B
ZOE:F Zoetis Inc

+5.60 (+3.94%)

USD 64.18B
TKD:F Takeda Pharmaceutical Company ..

-0.30 (-1.22%)

USD 39.41B
TKDA:F Takeda Pharmaceutical Company ..

-0.10 (-0.83%)

USD 39.17B
H6D0:F Haleon PLC

+0.02 (+0.57%)

USD 34.71B
H6D:F Haleon PLC

+0.10 (+1.37%)

USD 34.27B
TEV:F Teva Pharmaceutical Industries..

+0.70 (+5.69%)

USD 14.69B
SH0:F Shionogi & Co. Ltd

+0.60 (+1.42%)

USD 12.76B
NB3:F Neurocrine Biosciences Inc

-0.35 (-0.27%)

USD 12.70B

ETFs Containing HAEK:F

XUT:CA iShares S&P/TSX Capped Ut.. 11.33 % 0.62 %

-0.05 (0.49%)

CAD 0.32B
ZUT:CA BMO Equal Weight Utilitie.. 6.91 % 0.60 %

-0.14 (0.49%)

CAD 0.41B
XDIV:CA iShares Core MSCI Canadia.. 6.52 % 0.11 %

+0.13 (+0.49%)

CAD 1.04B
FAI:CA 5.05 % 1.14 %

N/A

N/A
DXM:CA 3.51 % 0.67 %

N/A

N/A
FCCD:CA Fidelity Canadian High Di.. 3.22 % 0.00 %

+0.07 (+0.49%)

CAD 0.16B
DWX SPDR® S&P International .. 1.50 % 0.45 %

+0.01 (+0.49%)

USD 0.45B
SCHC Schwab International Smal.. 0.47 % 0.12 %

+0.31 (+0.49%)

USD 3.95B
VSS Vanguard FTSE All-World e.. 0.31 % 0.12 %

+0.97 (+0.49%)

USD 8.25B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.15% 8% B- 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.15% 8% B- 6% D-
Trailing 12 Months  
Capital Gain -8.49% 51% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.49% 46% F 38% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.39% 63% D 44% F
Dividend Return -1.39% 59% D- 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.17% 57% F 47% F
Risk Adjusted Return -6.01% 61% D- 44% F
Market Capitalization 0.11B 51% F 32% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector